Unadjusted comparisons of induction cisplatin and capecitabine ( PX ) versus adjuvant PF indicated a favorable trend in progression-free survival for the conventional fractionation arm ( P = @ ) ; analyses that were adjusted for other significant factors and fractionation reflected a significant reduction in the hazards of disease progression ( hazard ratio -LSB- HR -RSB- , @ ; @ % confidence interval -LSB- CI -RSB- , @-@ @ ) and death ( HR , @ ; @ % CI , @-@ @ ) .